- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07236671
Progression Patterns of Choroidal Venous Alterations (CVA)
November 21, 2025 updated by: Gemmy Cheung Chui Ming, Singapore National Eye Centre
International Multi-centre, Prospective, Longitudinal Cohort to Evaluate the Progression Pattern of Choroidal Venous Alterations
This study is about understanding how a condition called pachychoroid changes over time.
Pachychoroid refers to an anatomic choroidal characteristic with abnormally thick choroid or abnormally dilated Haller's vessels.
Pachychoroid can range from mild forms which does not cause any problems to more serious ones that might cause vision loss.This study will recruit participants with pachychoroid, to learn more about how this condition develops, how it affects people in the long run, and what factors might make it worse.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This study aims to document the longitudinal progression pattern and the incidence rate of progression of choroidal venous alteration (defined as either an increase in number of quadrants with pachyvessels or formation of new anastomoses which violates the physiological watershed It will provide valuable natural history data to study the pattern of evolution of choroidal vessels over time and validate the proposed multi-hit theory over a period of three years.
Study Type
Observational
Enrollment (Estimated)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gemmy Cheung
- Phone Number: +65 63227460
- Email: gemmy.cheung.c.m@singhealth.com.sg
Study Locations
-
-
-
Hong Kong, Hong Kong
- Not yet recruiting
- Hong Kong University
-
Contact:
- Angie Fong
- Phone Number: 852 2518 1430
- Email: fongahc@hku.hk
-
-
-
-
-
Kuala Lumpur, Malaysia
- Recruiting
- University of Malaya Medical Centre
-
Contact:
- Lott Pooi Wah Dr
- Phone Number: 03-79677022
- Email: lottpw@um.edu.my
-
-
-
-
-
Singapore, Singapore
- Not yet recruiting
- National University Hospital, Singapore
-
Contact:
- Wendy Wong
- Phone Number: +65
- Email: wendy_wong@nuhs.edu.sg
-
Singapore, Singapore
- Recruiting
- Singapore National Eye Centre/ Singapore Eye Research Institute
-
Contact:
- Gemmy Cheung
- Phone Number: +65 63227460
- Email: gemmy.cheung.c.m@singhealth.com.sg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
This study will aim to recruit 170 participants in Singapore National Eye Centre (SNEC) and 50 participants in National University Hospital, 30 participants from the University of Malaya
Description
Inclusion Criteria:
- Adults aged 45 years or older.
- Presence of pachyvessels on ultra-widefield (UWF) imaging in at least one quadrant.
- Willing to undergo pupil dilation, and protocol-required procedures for both eyes
- Willing to provide written informed consent
Exclusion Criteria:
- Presence of disorders of the ocular media which interfere with visual acuity and other ocular assessments during the study period
- Eyes with other ocular pathology such as trauma, inflammation, previous intraocular surgery (except for cataract surgery)
- Systemic diseases that might affect ocular blood flow such as uncontrolled hypertension, autoimmune disease, and haematological disorders
- Pregnant or nursing women
- Persons who are unable to give informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression of choroidal venous alterations
Time Frame: 3 years
|
Proportion of eyes demonstrating progression of choroidal venous alterations, defined as either an increase in number of quadrants with pachyvessels or formation of new choroidal anastomoses.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of progression of pachychoroid disease manifestation
Time Frame: 3 years
|
New onset of Central Serous Chorioretinopathy (CSCR), focal Retinal Pigment Epithelium (RPE) changes, or other pachychorois related findings.
|
3 years
|
|
Risk factors associated with progression of choroidal venous alteration
Time Frame: 3 years
|
Assessment of demographic, cilinical, and imaging parameters associated with progression.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2025
Primary Completion (Estimated)
June 1, 2029
Study Completion (Estimated)
August 1, 2029
Study Registration Dates
First Submitted
November 14, 2025
First Submitted That Met QC Criteria
November 14, 2025
First Posted (Estimated)
November 19, 2025
Study Record Updates
Last Update Posted (Actual)
November 28, 2025
Last Update Submitted That Met QC Criteria
November 21, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- 2024-4359
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pachychoroid Disease
-
Singapore National Eye CentreRecruitingPachychoroid DiseaseSingapore
-
Singapore National Eye CentreNational University Hospital, SingaporeCompleted
-
Kim's Eye HospitalNune Eye Hospital, Seoul, Korea; HanGil Eye HospitalCompletedPachychoroid NeovasculopathyKorea, Republic of
-
ClinactAssociation CRO - Tous unis pour la visionRecruitingOcular Rosacea | Pachychoroid DiseaseFrance
-
Yeungnam University College of MedicineNovartisNot yet recruitingAge-Related Macular Degeneration | Pachychoroid Neovasculopathy
-
IRCCS San RaffaeleNot yet recruitingUveitis | Diabetic Retinopathy | Diabetic Macular Edema | Retinal Vein Occlusion | Geographic Atrophy | Myopia | Ocular Surface Disease | Stargardt Disease | Retinitis Pigmentosa (RP) | Vitreoretinal Disease | Best Disease | Pachychoroid Disease | Central Serous Choroidopathy | Age - Related Macular Degeneration (AMD) and other conditions
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
St. Lawrence Health SystemNot yet recruitingInterstitial Lung Disease Due to Systemic Disease | Interstitial Lung Disease Due to Systemic Disease (Disorder) | Interstitial Lung Disease in Patients With Rheumatoid ArthritisUnited States